Sublimity Therapeutics is a clinical-stage biotechnology company dedicated to identifying and developing meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Led by a team of industry innovators and leveraging our Single-Multiple Pill (SmPill®) technology, we are advancing a diverse pipeline of oral small molecules that have the potential to make important contributions to human health. Our lead asset ST-0529 is currently being evaluated in the AURORA (CYC-202) Study, a Phase 2b clinical trial for moderate to severe Ulcerative Colitis.
Company Details
- Employees
- 8
- Address
- Dcu Alpha Innovation Campus, Old Finglas Road, Dublin,11 D11 Kxn4,ireland
- Phone
- (353) 170-0751
- in****@****ics.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- sublimitytherapeutics.com
- Keywords
- Waltham.
- HQ
- Dublin, 11
Sublimity Therapeutics Questions
Sublimity Therapeutics's helpline number is (353) 170-0751
Sublimity Therapeutics's website is sublimitytherapeutics.com
Sublimity Therapeutics's LinkedIn profile is https://www.linkedin.com/company/sublimity-therapeutics
Sublimity Therapeutics has
8 employees.
View email and phone details for 8
employees at Sublimity Therapeutics.
Sublimity Therapeutics's industry is
Pharmaceutical Manufacturing
Sublimity Therapeutics's top competitors are
Atxa Therapeutics,
Inthelia Therapeutics,
Eirgen Pharma,
Solvotrin Therapeutics - Active Iron,
Ppd,
Iterum Therapeutics Plc,
Gh Research Plc,
Innopharma, Inc.,
Weatherbys Scientific,
Altrubio Inc..
Sublimity Therapeutics's support email address is info@sublimitytherapeutics.com
Sublimity Therapeutics's categories are Pharmaceutical Manufacturing
